Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchEnded earlyNCT03893019
What this trial is testing

MB-CART20.1 Melanoma

Who this might be right for
Melanoma (Skin)
Miltenyi Biomedicine GmbH 9
Early research (Phase 1)UnknownNCT06520319
What this trial is testing

Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma

Who this might be right for
Medullary Thyroid Carcinoma
First Affiliated Hospital of Fujian Medical University 20
Early research (Phase 1)Active Not RecruitingNCT04750954
What this trial is testing

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Neoplasm
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT04291105
What this trial is testing

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Who this might be right for
MelanomaHead and Neck Squamous Cell CarcinomaColo-rectal Cancer
Vyriad, Inc. 87
Testing effectiveness (Phase 2)Ended earlyNCT00612222
What this trial is testing

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Who this might be right for
Metastatic MelanomaSkin Cancer
National Cancer Institute (NCI) 4
Early research (Phase 1)Study completedNCT00375245
What this trial is testing

Rapamycin With Grapefruit Juice for Advanced Malignancies

Who this might be right for
TumorsNeoplasm Metastasis
University of Chicago 41
Testing effectiveness (Phase 2)Study completedNCT01237457
What this trial is testing

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine Tumors
Ebrahim S Delpassand 143
Not applicableActive Not RecruitingNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Testing effectiveness (Phase 2)Study completedNCT03304639
What this trial is testing

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Who this might be right for
Advanced Merkel Cell CarcinomaClinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8+5 more
National Cancer Institute (NCI) 9
Testing effectiveness (Phase 2)Looking for participantsNCT05655312
What this trial is testing

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Who this might be right for
Recurrent Melanoma (Skin)Metastatic MelanomaMelanoma Stage IV+1 more
Perspective Therapeutics 300
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00243594
What this trial is testing

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Who this might be right for
Melanoma Stage III or IV
Radboud University Medical Center 40
Testing effectiveness (Phase 2)UnknownNCT00086866
What this trial is testing

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Who this might be right for
Melanoma (Skin)
European Organisation for Research and Treatment of Cancer - EORTC 165
Not applicableStudy completedNCT03745872
What this trial is testing

SunSmart Intervention in Schools

Who this might be right for
Melanoma
University of Colorado, Denver 76
Testing effectiveness (Phase 2)Study completedNCT01743157
What this trial is testing

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
California Pacific Medical Center Research Institute 24
Not applicableUnknownNCT06121752
What this trial is testing

Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Asian Institute of Gastroenterology, India 54
Large-scale testing (Phase 3)Study completedNCT04552847
What this trial is testing

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven 85
Testing effectiveness (Phase 2)Study completedNCT00654238
What this trial is testing

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Who this might be right for
Metastatic Differentiated Thyroid CancerMetastatic Poorly Differentiated Thyroid CancerMetastatic Anaplastic Thyroid Cancer+1 more
University of Pennsylvania 59
Testing effectiveness (Phase 2)Ended earlyNCT00923247
What this trial is testing

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Who this might be right for
Medullary Thyroid Carcinoma
National Cancer Institute (NCI) 22
Not applicableStudy completedNCT07412158
What this trial is testing

Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)

Who this might be right for
Risk Grading SystemPheochromocytoma and Paraganglioma (PPGL)Quantitative Assessment
Peking University First Hospital 500
Next Page
116